Literature DB >> 2892664

Beta-adrenergic stimulation of growth hormone (GH) release in vivo, and subsequent inhibition of GH-releasing factor-induced GH secretion.

R J Krieg1, S N Perkins, J H Johnson, J P Rogers, A Arimura, M J Cronin.   

Abstract

In vivo and in vitro studies of beta-adrenergic influences on GH secretion have produced apparently conflicting data in which the in vivo effect seems to be inhibitory and the in vitro effect to be stimulatory. The present studies were designed to observe the in vivo effect of isoproterenol (ISO), a beta-adrenergic agonist, on 1) GH release during a brief interval after intraatrial infusion, and 2) GH release in response to GRF infused 10 min after ISO. ISO was found to stimulate GH release in both intact and hypothalamus-lesioned animals within 2 min after infusion, but GH returned to control levels within 10 min. ISO also profoundly inhibited the release of GH in response to GRF. Pretreatment of animals with somatostatin (SRIF) antiserum prevented the inhibitory action of ISO on GRF-induced GH release. No change in peripheral levels of SRIF was detected. Also, there was no suppression of GRF-induced GH release by ISO when the treatments were applied in vitro to dispersed perifused pituitary cells. These data show that beta-adrenergic systems can stimulate a rapid but brief release of GH in vivo, and that the subsequent inhibitory action on GRF-induced GH release might be by means of SRIF release.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2892664     DOI: 10.1210/endo-122-2-531

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis.

Authors:  A Giustina; M Malerba; E Bresciani; P Desenzani; M Licini; G Zaltieri; V Grassi
Journal:  J Endocrinol Invest       Date:  1995-12       Impact factor: 4.256

2.  Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans.

Authors:  E Arvat; J Ramunni; L Gianotti; L Di Vito; M Maccario; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

3.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

4.  The effect of medial forebrain bundle lesion on thyrotropin secretion in the rat.

Authors:  A Jaffer; W M Daniels; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1991-05       Impact factor: 3.996

5.  Effects of alpha 2- and beta-adrenoceptor agonists on growth hormone secretion following lesion of the noradrenergic system of the rat.

Authors:  A Jaffer; W M Daniels; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1992-12       Impact factor: 3.996

6.  Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children.

Authors:  E Ghigo; M R Valetto; L Gaggero; A Visca; F Valente; J Bellone; D Castello; F Camanni
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

7.  Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity.

Authors:  E Ghigo; E Bartolotta; E Imperiale; J Bellone; G Cardinale; G Aimaretti; M R Valetto; V Cherubini; M Maccario; D Cocchi
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

8.  The stimulation and inhibition of beta-2 adrenergic receptor on the inflammatory responses of ovary and immune system in the aged laying hens.

Authors:  Ali Hatefi; Ahmad Zare Shahneh; Zarbakht Ansari Pirsaraie; Ali Mohammad Alizadeh; Mohammad Pouya Atashnak; Reza Masoudi; Frederic Pio
Journal:  BMC Vet Res       Date:  2021-05-22       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.